We are live on ! Find out more
TLP

Tri Locum Partners Portfolio holdings

AUM $713M
1-Year Est. Return 68.92%
This Fund
S&P 500
This Quarter Est. Return
+33.46%
1 Year Est. Return
+68.92%
3 Year Est. Return
+377.81%
5 Year Est. Return
+1,289.15%
10 Year Est. Return
–
AUM
$247M
AUM Growth
-$117M
Cap. Flow
-$139M
Cap. Flow %
-56.36%
Top 10 Hldgs %
58.38%
Holding
95
New
54
Increased
7
Reduced
11
Closed
22

Top Buys

Rank Stock Value
1
WST icon
West Pharmaceutical
WST
+$23M
2
MRK icon
Merck
MRK
+$13M
3
AXSM icon
Axsome Therapeutics
AXSM
+$12M
4
APLS
Apellis Pharmaceuticals
APLS
+$11.8M
5
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$11.7M

Top Sells

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$24.2M
2
ARGX icon
argenx
ARGX
+$23.5M
3
NBIX icon
Neurocrine Biosciences
NBIX
+$20.9M
4
REGN icon
Regeneron Pharmaceuticals
REGN
+$20.7M
5
LLY icon
Eli Lilly
LLY
+$18M

Sector Composition

Rank Sector Weight
1 Healthcare 90.81%
2 Real Estate 0.3%
3 Industrials 0.1%
4 Financials 0.1%
5 Energy 0.07%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DOUG icon
51
Douglas Elliman
DOUG
$159M
$64K 0.03%
+16,574
New +$66.1K
CRMD icon
52
CorMedix
CRMD
$581M
$58K 0.02%
+13,812
New +$48.9K
PRAX icon
53
Praxis Precision Medicines
PRAX
$8.9B
$57K 0.02%
+1,610
New +$50.2K
EAF icon
54
GrafTech
EAF
$200M
$56K 0.02%
+1,187
New +$57.6K
ORGO icon
55
Organogenesis Holdings
ORGO
$305M
$50K 0.02%
+18,527
New +$54K
XERS icon
56
Xeris Biopharma Holdings
XERS
$1.4B
$49K 0.02%
+36,766
New +$51.9K
BVS icon
57
Bioventus
BVS
$1.03B
$44K 0.02%
+16,857
New +$73.6K
AMRX icon
58
Amneal Pharmaceuticals
AMRX
$5.89B
$43K 0.02%
+21,622
New +$48.5K
SLGC
59
DELISTED
SomaLogic, Inc. Class A Common Stock
SLGC
$42K 0.02%
+16,619
New +$46.4K
OMIC
60
DELISTED
Singular Genomics Systems, Inc. Common Stock
OMIC
$33K 0.01%
+541
New +$36.3K
PRDS
61
DELISTED
Pardes Biosciences, Inc. Common Stock
PRDS
$33K 0.01%
+19,757
New +$25K
PASG icon
62
Passage Bio
PASG
$14.8M
$31K 0.01%
+1,133
New +$28.6K
HBIO icon
63
Harvard Bioscience
HBIO
$28.7M
$28K 0.01%
+1,003
New +$24.7K
IVVD icon
64
Invivyd
IVVD
$178M
$22K 0.01%
+14,967
New +$41.6K
BYSI icon
65
BeyondSpring
BYSI
$40.1M
$20K 0.01%
+10,833
New +$10.2K
OVID icon
66
Ovid Therapeutics
OVID
$489M
$19K 0.01%
+10,009
New +$17.1K
SYBX
67
DELISTED
Synlogic
SYBX
$16K 0.01%
+1,397
New +$17.1K
PTE
68
DELISTED
PolarityTE, Inc. Common Stock
PTE
$16K 0.01%
+24,743
New +$18K
QNCX icon
69
Quince Therapeutics
QNCX
$28.2M
$14K 0.01%
+111
New +$18.6K
LMDX
70
DELISTED
LumiraDx Limited Common Shares
LMDX
$14K 0.01%
+15,621
New +$16.5K
MBIO icon
71
Mustang Bio
MBIO
$4.52M
$13K 0.01%
+44
New +$15K
IMDX
72
Insight Molecular Diagnostics
IMDX
$161M
$12K ﹤0.01%
+1,942
New +$21.4K
NGNE icon
73
Neurogene
NGNE
$718M
$5K ﹤0.01%
+512
New +$5.29K
ACLX
74
DELISTED
Arcellx
ACLX
– –
-42,826
Closed -$804K
ALLO icon
75
Allogene Therapeutics
ALLO
$673M
– –
-784,133
Closed -$8.47M
1 2
3
4

Similar funds

DCM
Defilade Capital Management Emeryville, California $712M AUM
AMPWP
Alvarez & Marsal Private Wealth Partners West Palm Beach, Florida $712M AUM
DCM
Dimension Capital Management Coral Gables, Florida $713M AUM 18.57% 1-Year Est. Return
IWP
Insight Wealth Partners Plano, Texas $713M AUM 16.55% 1-Year Est. Return
PCS
Personal CFO Solutions Chester, New Jersey $712M AUM 25.3% 1-Year Est. Return
ACGDR
Atmos Capital Gestao de Recursos Leblon - Rio De Janeiro, Brazil $714M AUM 35.97% 1-Year Est. Return
GEA
Glen Eagle Advisors Kingston, New Jersey $714M AUM 18.87% 1-Year Est. Return
ECM
EagleClaw Capital Management Boston, Massachusetts $714M AUM 24.24% 1-Year Est. Return

Tri Locum Partners's Q4 2022 Portfolio in Review

As of Q4 2022, Tri Locum Partners held 95 positions worth $247M, down 32% from $364M the previous quarter. Its ten largest holdings account for 58% of the portfolio.

Tri Locum Partners withdrew a net $139M in Q4 2022, closing 22 positions and reducing 11 holdings. Its most notable exit was Biogen, an estimated $24.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 91% of assets, down from 93% a quarter earlier, followed by Real Estate and Industrials.

Against the trend, Tri Locum Partners opened a new position in West Pharmaceutical worth $22.8M.

  • Tri Locum Partners's largest Q4 2022 buy was West Pharmaceutical: 97,084 shares worth $22.8M.
  • Tri Locum Partners added most to Sarepta Therapeutics in Q4 2022, an estimated $2.81M increase.
  • Tri Locum Partners's biggest Q4 2022 reduction was argenx, cutting an estimated $23.5M.
  • Tri Locum Partners fully exited Biogen in Q4 2022, selling an estimated $24.2M.
  • Tri Locum Partners's ten largest holdings make up 58% of its $247M portfolio in Q4 2022.
  • Tri Locum Partners opened 54 new positions and closed 22 in Q4 2022.
  • Tri Locum Partners's portfolio value fell 32% quarter-over-quarter to $247M.

Based on Tri Locum Partners's 13F filing for Q4 2022, filed 14 Feb 2023.